Dapagliflozin regulates autophagy in nephropathy associated with non-diabetic obesity via elevated plasma β-hydroxybutyrate levels.

Reamputation risk and mortality after lower-limb amputation in patients with diabetes: predictors, effects of antidiabetic medications and temporal trends.

Aquaporin-4 suppresses neuronal pyroptosis after ischemic stroke via the IκBα/NF-κB signaling pathway.

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes.

Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection.

Novel drugs targeting genetic variants: current applications and future prospects in heart failure treatment.

Is There a Role for Pentoxifylline in Diabetic Kidney Disease?

p38MAPK protects against myocardial ischemia-reperfusion injury by regulating GLUT4 expression and translocation through MEF2A/MEF2C in isolated rat heart.

Early seizures and heterogeneity of physiologic recovery in heat-related illness: a nationwide registry study.

Predictors of Discontinuation of Angiotensin Converting Enzyme Inhibitors Use Among Medicare Beneficiaries Using Sodium-Glucose Cotransporter 2 Inhibitors.

Role of liver X receptors in the pathogenesis and treatment of chronic liver disease (Review).

Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).

Sweat components as a promising monitoring tool for systemic diseases.

Quantifying the Age of Evidence: Lessons From Cardiovascular Drugs.

MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome.

Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through AMPK Activation and Angiotensin II Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome.

Condition of calves on arrival at dairy-beef calf-raising farms in the Midwestern US.

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review.

Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI).

The differential expression of lipocalin-2 in pig tissues and its molecular mechanism of regulating cell viability, differentiation, adipogenesis, and glycometabolism in porcine intramuscular preadipocytes.

Inosine promotes erythrocyte metabolic reprogramming and restores oxygen release for rejuvenation via 2,3-BPG-PNP axis.

The role of combining exercise with pharmacologic management of CKD: From SGLT2 and GLP-1 to broader therapeutic strategies.

Microglial fructose metabolism is essential for glioblastoma growth.

Mendelian Randomization Identified SLC2A9 as a Novel cis-eQTL-Mediated Susceptibility Gene in Suppressing Renal Cancer and Its Related Metabolic Mechanisms.

The primary preventive effect of sodium-glucose cotransporter inhibitors on chronic kidney disease in patients with type 2 diabetes: a systematic review and meta-analysis.

Diabetic retinopathy severity is associated with renal function deterioration in patients with diabetic kidney disease: a retrospective cohort study.

KNDC1 attenuates fibrosis in nonalcoholic fatty liver disease by inhibiting glycolysis in hepatic stellate cells.

Glycohypoxia: a hypothesis linking chronic hyperglycemia to functional hypoxia and diabetic complications in type 2 diabetes.

Clinical, practical, and psychosocial challenges of living with glucose transporter type 1 deficiency syndrome.

Early changes in kidney function in young adults: what is the significance?

Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis.

SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob.

Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes-A Narrative Review.

A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.

Epigenetic effects of alcohol consumption on type 2 diabetes.

Maternal exposure to sucrose and maltodextrin alters metabolism and genotoxicity in mice offspring.

Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2).

Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study.

Empagliflozin and dapagliflozin, sodium glucose cotransporter 2 inhibitors, may improve cognitive dysfunctions: in silico and in vivo findings.

Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy.

The SGLT2 Inhibitor Canagliflozin Promotes β-Cell Regeneration and Restores and Stabilises β-Cell Identity in a Polygenic Model of Severe Early-Onset Type 2 Diabetes.

Metabolically reprogrammed eosinophils impair T cell immunity and cause chronic skin infection.

Evaluation of a pharmacist-led medication review and optimisation service in the management of cardiometabolic disease.

Sodium glucose co-transporter inhibition as a strategy to stabilize the microvasculature in sickle cell disease.

Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.

Untargeted Proteomics Profiling of Liver and Plasma in Fed and Fasted Liver-Specific Glycogen Storage Disease Type Ia (GSD Ia) Mice: Toward Potential Protein Biomarkers.

Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease.

Impact of SGLT2 inhibitors in patients with Fabry disease.

Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study.

Beyond expensive innovations: affordable and effective strategies for managing tubulopathies in adults.

Gut-Derived Hippuric Acid Alleviates Hepatic Lipid Metabolism via UGDH/FOXK1/CD36 Axis in Obese Mice.

USP8 attenuates ischemic stroke by inhibiting the microglial NF-κB/NLRP3 inflammatory axis via TRAF6 deubiquitination.

Sodium-glucose Co-transporter 2 (SGLT2) inhibitor dapagliflozin acutely activates cardiomyocyte HIF-1α signaling via succinate, a signaling metabolite.

Neomycin-sensitive gut bacteria-derived brassicasterol mediates the anti-obesity effects of Cordyceps militaris polysaccharide.

Impact of risperidone and voluntary exercise on ketone body metabolism-related gene expression in the brain of female juvenile rats.

Chronic Pyraclostrobin Exposure-Induced Developmental Toxicity and ABC Transporter-Associated Metabolism Disorders during Zebrafish Embryo-Larval Stages.

Sodium-Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction-Associated Steatohepatitis.

Pax8-rtTA/LC1-Driven Inducible Ketohexokinase Deletion Protects Against High Fructose-Induced Metabolic Syndrome in Mice.

SGLT2 inhibitors therapy in patients with acute Takotsubo syndrome.

CX3CR1/P2X4R signaling-mediated spinal microglial M1 polarization contributes to chronic pelvic pain in endometriosis.

Multi-dimensional evidence establishing the causal association between metabolic syndrome and gout and the molecular mechanisms of comorbidity.

Pyroptosis-mediator Gasdermin D in serum: a potential biomarker in diabetic kidney disease.

Integrative multi-omics analysis reveals cellular and molecular insights into gestational diabetes mellitus.

A therapeutic role for a regulatory glucose transporter1 (GLUT1)-associated lncRNA in GLUT1-deficient mice.

[Modern treatment of type 2 diabetes: 3 medications and 3 targets].

Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.

The metabolic balancing act between fatty acid and glucose substrate use for optimal myocardial function: Key role for membrane substrate transporters.

Factors Associated With Loop Diuretic De-escalation in Patients With Acute Decompensated Heart Failure: The Influence of Guideline Directed Medical Therapy Initiation.

GPIHBP1 Autoantibody-Related Hypertriglyceridemia in a 12-Year-Old Girl With Systemic Lupus Erythematosus.

An experimental study on shrimp bioactive peptides restoring testicular function in a rat model of fatty liver disease via autophagy, redox balance, and energy transporters.

Technology-enabled insights into SLC transporters in MAFLD: redefining the multi-hit pathogenesis and therapeutic landscape.

Practical Guidance on Implementation of Guideline-Directed Medical Therapy in the Management of Heart Failure: Expert Opinion From the Middle East and Africa Region.

Higher hemoglobin levels within reference interval are associated with elevated cardiometabolic traits in a birth cohort of 16-yr-old adolescents.

Alport syndrome complicated with IgA nephropathy: a case report.

Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis.

Aetiological Description of Urinary Tract Infections in Patients with Type 2 Diabetes and Construction of a Clinical Prediction Model: A Retrospective Study.

ALG8-Driven Metabolic Reprogramming in Polycystic Kidney Disease: A Systematic Synthesis of Evidence Linking Glycosylation Defects to Metabolic Signaling.

Predicting metabolic syndrome risk in Chinese adults using integrated features of movement behaviors and dietary intake: a machine learning approach.

Association between SGLT2 inhibitors and recurrence of cerebrovascular events in patients with type 2 diabetes: A population-based cohort study.

Analyses of astrocyte-neuron lactate shuttle transporter levels in brain tissues from people with HIV-associated neurocognitive impairment and Alzheimer's disease.

Identifying Provider Prescribing Practices for GLP-1RAs and SGLT-2is in Patients With Type 2 Diabetes to Address Pharmacoinequity.

Adaptive Responses to High-fructose Corn Syrup Intake Under Energy Restriction in Early Middle-aged Female Mice.

Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure.

[Prevention and screening in nephrology].

SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium-Treated Patients With Mood Disorders: A Real-World Historical Cohort Study.

Therapeutic Efficacy of S-Allyl-L-Cysteine an Active Constituent of Aged Garlic Extract in Rat Model of Gestational Diabetes Mellitus.

A Novel Autoimmune Presentation of Wiskott-Aldrich Syndrome: Type 1 Diabetes.

γ-Oryzanol Ameliorates Endothelial Replicative Senescence via Downregulation of SGLT2 Expression to Attenuate NADPH-Driven Oxidative Stress.

Computational Discovery of Novel SGLT2 Inhibitors from Eight Selected Medicine Food Homology Herbs Using a Multi-Stage Virtual Screening Pipeline.

PPAR-γ Activation Alleviates Intestinal Dysfunction and Lactose Malabsorption in Experimental Food Allergy Rats.

Sex and Gender Differences in Chronic Kidney Disease-Explained by the Brenner-Luyckx Concept of Hyperfiltration.

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Beyond Blood Pressure: Salt Sensitivity as a Cardiorenal Phenotype-A Narrative Review.

Utilization Trends of SGLT2 Inhibitors in Croatian Clinical Practice: Observational Analysis.

A Novel PPARG R212W Variant Causes Familial Partial Lipodystrophy Type 3: Clinical Presentation and Functional Characterization.

Mitigation of Ischemia/Reperfusion-Induced Acute Kidney Injury by Canagliflozin Is Associated with Altered Mitochondrial Dynamics and Reduced Proliferation in Swine.

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

The link between caveolae, metabolic syndrome, and cataractogenesis: A mechanistic hypothesis.

Absolute Quantification of Full-Length 16S rRNA Amplicon Sequencing and Metabolomic Profiling of Red-Stipe Disease in Morel Fruiting Bodies.

Plasma Metabolites Associated with CKD Stage in Autosomal Dominant Tubulointerstitial Kidney Disease.

Co-Exposure to Bisphenol A and a High-Fat Diet Induces Insulin Resistance via Suppression of Insulin Signaling Molecule Expression and GLUT4 Translocation.

Brain Ketone Bodies in Health, Evolution and Disease.

Alternative methods for pharmacological research on the action mechanisms of natural products used in the treatment of type 2 diabetes: a systematic review.

Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.

ADGRL4 induces adipose browning and weight loss via AKT activation.

Glucosuria as a Biomarker of Adherence to Sodium-Glucose Co-Transporter Protein Type 2 Inhibitors.

Heterogeneous Kidney Patterns in Diabetic Patients Following SGLT2 Inhibitor Use.

Evaluating Therapeutic Efficacy of SCL7A11 and GLUT1 Inhibition in Triple-Negative Breast Cancer via a GSH/ATP Dual-NIR-Responsive Fluorogenic Sensor.

Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.

The IGF2BP3/SLC2A1 axis mediates hsa_circ_0000376-Induced malignant progression and neutrophil N2 polarization in the lung adenocarcinoma microenvironment.

Sodium Glucose Co-transporter 2 Inhibitor associated perioperative Diabetic Ketoacidosis.

Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis.

SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study.

Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.

Comparative risk of the neurodegenerative outcomes between sodium-glucose co-transporter 2 (SGLT2) inhibitors and thiazolidinediones in type 2 diabetes: a multicentre cohort study using the Korean healthcare database (2014-2025).

Dapagliflozin alleviates renal fibrosis in type 2 diabetic mice through regulating STAT3.

Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.

Medicinal chemistry advances of SGLT inhibitors: SAR, structural innovation, and mechanistic insights.

Glucose transporter 3 gene deficiency modifies Huntington's disease progression in zQ175 model mice.

Red blood cells serve as a primary glucose sink to improve glucose tolerance at altitude.

Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats.

Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention.

Concurrent management of gout and type 2 diabetes mellitus: combined therapy insights.

Early initiation of sodium-glucose co-transporter-2 inhibitors in heart failure patients: a nationwide study.

Finerenone with Empagliflozin in CKD with diabetes (CONFIDENCE): Only a blood pressure effect? Likely!

Bridging the gap in heart failure management: the effect of a cross-disciplinary intervention on guidelines-directed medical therapy in primary care.

Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.

SGLT2 Inhibitor-Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study.

Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 axis disrupts metabolic-epigenetic crosstalk and suppresses progression in hyperglycolytic breast cancer.

Knowledge and attitudes toward ketogenic dietary therapy in adults with epilepsy.

Glycemic Impact of Non-Nutritive Sweeteners in Health and Type 2 Diabetes.

Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study.

Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.

[PET in Neurology: Imaging Pathology, Metabolism, and Disease Progression].

Type 1 Diabetes: A Review.

Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction.

Non-invasive identification of brain signatures of acute liver injury.

Clinical worsening in adult congenital heart disease and heart failure: A single-centre, observational study.

Anti-obesity effects of Withania somnifera and Chrysanthemum zawadskii Herbich var. latilobum (Maxim.) Kitamura by regulating lipid metabolism and insulin signaling in 3T3-L1 adipocytes.

Clinical Utility of Genetic Diagnosis in Drug-Resistant Epilepsy: Refining Classification and Guiding Therapy in an Egyptian Cohort.

[The effect of empagliflozin on the quality of life in patients with heart failure: results from the Hungarian cohort of the international Emp-Activity study].

More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases.

A peptide drug targeting SASH1-PKM2 interaction promotes recovery of traumatic brain injury in mice.

Topical ionic liquid-mediated GLUT1 gene editing ameliorates psoriasis and prevents recurrence.

USP30-mediated Deubiquitination of Hexokinase 2 controls the metabolic fate of glucose and tumor progression.

Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort.

Saquinavir induces pyroptosis through the OTUD5-JAK1-GSDME axis in hepatocellular carcinoma.

Tumor visualization and evaluation of glioblastoma in mice using small animal 9.4T MRI and PET‑CT with high resolution.

High Glucose-Induced Alterations in Regucalcin Expression in Podocytes and Their Potential Consequences.

Neurochemical and Energetic Alterations in Depression: A Narrative Review of Potential PET Biomarkers.

Insulin Resistance and Inflammation.

Insulin Signaling in Alzheimer's Disease: Association with Brain Insulin Resistance.

Cinnamon-Derived Phytonutrients as Modulators of Ion Channels and G Protein-Coupled Receptor Signaling in Metabolic Diseases.

Nuciferine Ameliorates Lipotoxicity-Mediated Myocardial Ischemia-Reperfusion Injury by Reducing Reverse Electron Transfer Mediated Oxidative Stress.

Lower Selenoprotein P Is Independently Associated with Peripheral Arterial Disease in Peritoneal Dialysis.

Effect of common diabetes medications on metabolic dysfunction-associated steatotic liver disease as measured by transient elastography and other metabolic parameters: A systematic review.

In silico assessment of benzyl C-analogues of dapagliflozin as potential SGLT2 inhibitors for type 2 diabetes.

High vulnerability of medial prefrontal pyramidal neurons in post-stroke, vascular, Alzheimer's disease, and aging-related dementias.

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic kidney disease: a meta-analysis.

Prevalence and outcomes of DKA in type 1 and type 2 DM patients treated and not treated with SGLT-2 inhibitors.

Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression.

Ethanol Alters DNMT1/3a/3b Expression Profile, Promotes Persistent DNA Hypomethylation in Human Brain Endothelial Cells and Impairs Late Cortical Angiogenesis.

Characteristics of Veterans with CKD Using a Telenephrology Program in the Veterans Health Administration.

Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes.

SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis.

Signal-Level Determinants of Cognitive Decline With PPIs versus H2RAs: Transportome (CBLIF/TCN2) and CHRNA7 Nodes.

Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes.

Dorzagliatin shows potential in preventing cognitive impairment in diabetes: evidence from Mendelian randomization analysis and animal study.

Bee pollen-derived peptide with dual DPP-IV Inhibition and glucose transport modulation.

Atypical protein kinase C activation drives intestinal glucose excretion in diabetes mellitus.

USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibiting glucose uptake.

Translational roadmap of BBB-targeted nanoparticle strategies for neuroregenerative therapy in neurodegenerative diseases.

Reprogramming of host energy metabolism mediated by the TNF-iNOS-HIF-1α axis plays a key role in host resistance to Plasmodium infection.

Estimation of metabolic water production in human and rat brain and spinal cord.

Chronic Kidney Disease, Nutrition, and the Brain: How to Maintain Brain Health Through Nutrition in Chronic Kidney Disease.

Dapagliflozin targets RORγt to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4+ T cell/Th17 cell axis within cardiac tissue.

Influence of chronic obstructive pulmonary disease on cardiovascular outcomes and mortality benefits of sodium glucose co-transporter inhibitors in heart failure patients: A systematic review and meta-analysis.

Exploring the Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review.

Single-Cell Multimodal Profiling Highlights Persistent Aortic Smooth Muscle Cell Changes in Diabetic Mice Despite Glycemic Control.

Perioperative management with close renal function monitoring in a dental patient receiving SGLT2 inhibitor therapy for non-diabetic chronic kidney disease.

Mild hypothermia (35°C) reduces myocardial ischemia-reperfusion injury and attenuates hypoxia induced apoptosis of H9C2 cardiomyocytes by changing the phosphorylation level of Connexin43 (Cx43) protein.

The role of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in chronic obstructive pulmonary disease.

In search of "what really matters": Insights from a web-based survey on Patient-Centered Outcomes in GLUT1DS.

Novel diethylthiosulfinate suppresses postharvest peach brown rot in vitro and vivo by disrupting carbon metabolism and virulence pathways in Monilinia fructicola.

Implementation of a peer mentorship program for type 1 diabetes in Canada: A qualitative analysis of peer mentor perspectives.

Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.

Therapeutic effects of vitamin D and intermittent fasting on metabolic associated steatotic liver disease in rats.

Chronic NH4Cl loading improves glucose tolerance without modifying insulin sensitivity in mice.

Acute effects of selective serotonin reuptake inhibitors on cerebral glucose metabolism and blood flow.

Folate receptor 1 activation suppresses high glucose-induced amyloidogenesis in neurons via STAT3/Nrf2 pathway-dependent mitigation of mitochondrial oxidative stress.

Targeting mitochondrial quality control in diabetic kidney disease: emerging therapeutic opportunities.

Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives.

Bioinformatics study of the pharmacological mechanism of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus and coronary heart disease based on network pharmacology.

Providing a supplemental source of water or a trace-mineral-based drinking solution upon feedlot arrival affects intake, growth performance, and health of newly received finishing calves.

Cholecystectomy inhibits fasting hepatic fatty acid oxidation in mice.

The eGFR Slope After Starting Therapy with Empagliflozin in a Cohort of Patients with Diabetes and Stage 3 CKD: Is It Really an Issue? TEMPOREALE Real-World Study.

Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV).

Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model.

Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway.